Cheaper MS drug could match costly standard in new trial

NCT ID NCT05758831

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether rituximab, a less expensive drug, works as well as ocrelizumab for people with relapsing-remitting multiple sclerosis. About 386 participants will receive either drug and be followed for 2 years. The main goal is to see if rituximab can keep the disease inactive (no relapses or new brain lesions) just as effectively as ocrelizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rituximab and ocrelizumab (infused drugs)
What this could lead to
If rituximab works as well as ocrelizumab, it could offer a more affordable treatment option for relapsing-remitting MS.
What could go wrong
This is a non-inferiority trial, so rituximab might not be as effective. Both drugs have known risks like infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HM - Hôpital la Timone

    RECRUITING

    Marseille, 13385, France

  • AP-HP Höpital la Pitié-Salpétrière

    NOT_YET_RECRUITING

    Paris, 75010, France

  • CHRU de Brest - Hôpital la Cavale Blanche

    NOT_YET_RECRUITING

    Brest, 29609, France

  • CHRU de Montpellier - Hôpital Gui de Chauliac

    RECRUITING

    Montpellier, 34295, France

  • CHRU de Strasbourg - Hôpital Hautpierre

    RECRUITING

    Strasbourg, 67200, France

  • CHU de Nantes -Hôpital Nord Laennec

    RECRUITING

    Nantes, 44800, France

  • CHU de Nice - Hôpital Pasteur 2

    RECRUITING

    Nice, 06002, France

  • CHU de Nîmes - Hôpital Caremeau

    NOT_YET_RECRUITING

    Nîmes, 30029, France

  • CHU de Rouen - Hôpital Charles Nicolle

    NOT_YET_RECRUITING

    Rouen, 76038, France

  • CHU de Toulouse - Bâtiment Pierre Paul Riquet

    NOT_YET_RECRUITING

    Toulouse, 31059, France

  • Centre Hospitalier Régional de Nancy

    RECRUITING

    Nancy, 54035, France

  • Centre Hospitalier Universitaire de Caen

    RECRUITING

    Caen, 14033, France

  • Centre Hospitalier Universitaire de Limoges

    NOT_YET_RECRUITING

    Limoges, 87042, France

  • Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou

    RECRUITING

    Rennes, 35000, France

  • Centre Hospitalier de Cornouaille

    RECRUITING

    Quimper, 29107, France

  • Centre Hospitalier de Pontoise - GHT NOVO

    NOT_YET_RECRUITING

    Cergy-Pontoise, 95300, France

  • Centre hospitalier de Gonnesse

    NOT_YET_RECRUITING

    Gonesse, 95503, France

  • Groupe Hospitalier Universitaire Henri Mondor

    NOT_YET_RECRUITING

    Paris, 94000, France

  • Groupe Hospitalier de l'Institut Catholique de Lille

    NOT_YET_RECRUITING

    Lille, 59160, France

  • Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer

    NOT_YET_RECRUITING

    Lyon, Bron, 69677, France

  • Hôpital Foch

    NOT_YET_RECRUITING

    Suresnes, 92150, France

  • Hôpital Gabriel Montpieds

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63003, France

  • Hôpital Saint-Germain

    NOT_YET_RECRUITING

    Poissy, 78303, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.